Compare Bilibili Inc (BILI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Merck & Co., Inc. — how do they compare? Bilibili Inc trades at $17.81 (market cap $7.35B), while Merck & Co., Inc. trades at $123.94 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 40.6× Bilibili Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| BILI | MRK | |
|---|---|---|
Market Cap | $7.35B | $298.31B |
Sector | Media | Health |
52-Week High | $35.92 | $129.52 |
52-Week Low | $15.96 | $77.60 |
Enterprise Value | $5.20B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.59, down 0.62% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.19, beating expectations, and maintains strong analyst support with 83.3% buy ratings. Revenue growth is steady, projected at $30.8B for 2026, with improving net income margins. Recent news highlights a new $300 million share repurchase program, signaling confidence in long-term value.
The outlook for BILI is cautiously optimistic, driven by earnings beats and shareholder-friendly actions, but risks include competitive pressures in the Chinese digital media space and technical bearishness. Upside potential hinges on sustained user growth and margin expansion, while volatility from market sentiment poses a near-term challenge.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
